FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116713827> ?p ?o ?g. }

• W2116713827 endingPage "1392" @default.
• W2116713827 startingPage "1392" @default.
• W2116713827 abstract "Isotretinoin is the most effective treatment for acne. The ideal dosing regimen is unknown.To determine the rates of relapse of acne vulgaris and retrial of isotretinoin after high cumulative-dose treatment and the changes to the adverse effect profile.A prospective, observational, intervention study was conducted from August 1, 2008, to August 31, 2010, in a single academic tertiary care center with multiple providers. A total of 180 patients with acne resistant to other treatments were enrolled. Of these, 116 participated in the 12-month follow-up survey, for a response rate of 64.4%.Patients received isotretinoin, with dosing based on the providers' judgment. Patients were divided into 2 groups on the basis of cumulative dosing (<220 mg/kg and ≥ 220 mg/kg).Relapse (treatment with a prescription topical or oral acne medication after a course of isotretinoin) or retrial (retreatment with isotretinoin) at 12-month follow-up and adverse effects experienced during and after 12 months of treatment. RESULTS The mean age of the participants was 19.3 years, 51.9% were female, and 74.1% were white. At 12 months' follow-up, 97.4% of the patients reported that their acne was improved. Overall, acne in 32.7% of patients in the study relapsed at 12 months, and 1.72% of the patients required a retrial. In the lower-dose treatment group (<220 mg/kg), the relapse rate was 47.4% (95% CI, 32.3%-63.0%) compared with 26.9% (95% CI, 18.3%-37.8%) in the high-dose group (P = .03). Almost 100% of the patients in both treatment groups developed cheilitis and xerosis during treatment. Retinoid dermatitis was significantly more common in the high-dose treatment group (53.8% vs 31.6%; P = .02). None of the other adverse effects was significantly different between the 2 groups.The dosing regimen used in the present study is considerably higher than that used in previous studies of isotretinoin. At 1 year after completion of isotretinoin treatment, we found that patients receiving 220 mg/kg or more had a significantly decreased risk of relapse. Rash was the only adverse effect that was significantly more common in the high-dose group during treatment. This study suggests that significantly higher doses of isotretinoin are effective for treating acne and decreasing relapse rates without increasing adverse effects." @default.
• W2116713827 created "2016-06-24" @default.
• W2116713827 creator A5035931681 @default.
• W2116713827 creator A5045299353 @default.
• W2116713827 creator A5052690775 @default.
• W2116713827 creator A5069977124 @default.
• W2116713827 creator A5070257158 @default.
• W2116713827 date "2013-12-01" @default.
• W2116713827 modified "2023-10-16" @default.
• W2116713827 title "High-Dose Isotretinoin Treatment and the Rate of Retrial, Relapse, and Adverse Effects in Patients With Acne Vulgaris" @default.
• W2116713827 cites W1498067332 @default.
• W2116713827 cites W1586425912 @default.
• W2116713827 cites W1607774051 @default.
• W2116713827 cites W1894495389 @default.
• W2116713827 cites W1953690218 @default.
• W2116713827 cites W1969067090 @default.
• W2116713827 cites W1972778383 @default.
• W2116713827 cites W1973337644 @default.
• W2116713827 cites W1977750773 @default.
• W2116713827 cites W1993932495 @default.
• W2116713827 cites W2003650561 @default.
• W2116713827 cites W2008336408 @default.
• W2116713827 cites W2026971310 @default.
• W2116713827 cites W2036922943 @default.
• W2116713827 cites W2043157381 @default.
• W2116713827 cites W2055610347 @default.
• W2116713827 cites W2065245096 @default.
• W2116713827 cites W2067487915 @default.
• W2116713827 cites W2069107618 @default.
• W2116713827 cites W2069661532 @default.
• W2116713827 cites W2084233582 @default.
• W2116713827 cites W2097683008 @default.
• W2116713827 cites W2097802363 @default.
• W2116713827 cites W2106433568 @default.
• W2116713827 cites W2109592716 @default.
• W2116713827 cites W2133888101 @default.
• W2116713827 cites W2135050705 @default.
• W2116713827 cites W2146675394 @default.
• W2116713827 cites W2147391196 @default.
• W2116713827 cites W2160490226 @default.
• W2116713827 cites W2467597593 @default.
• W2116713827 cites W27984251 @default.
• W2116713827 cites W32947034 @default.
• W2116713827 cites W61315535 @default.
• W2116713827 cites W95894692 @default.
• W2116713827 doi "https://doi.org/10.1001/jamadermatol.2013.6746" @default.
• W2116713827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24173086" @default.
• W2116713827 hasPublicationYear "2013" @default.
• W2116713827 type Work @default.
• W2116713827 sameAs 2116713827 @default.
• W2116713827 citedByCount "92" @default.
• W2116713827 countsByYear W21167138272013 @default.
• W2116713827 countsByYear W21167138272014 @default.
• W2116713827 countsByYear W21167138272015 @default.
• W2116713827 countsByYear W21167138272016 @default.
• W2116713827 countsByYear W21167138272017 @default.
• W2116713827 countsByYear W21167138272018 @default.
• W2116713827 countsByYear W21167138272019 @default.
• W2116713827 countsByYear W21167138272020 @default.
• W2116713827 countsByYear W21167138272021 @default.
• W2116713827 countsByYear W21167138272022 @default.
• W2116713827 countsByYear W21167138272023 @default.
• W2116713827 crossrefType "journal-article" @default.
• W2116713827 hasAuthorship W2116713827A5035931681 @default.
• W2116713827 hasAuthorship W2116713827A5045299353 @default.
• W2116713827 hasAuthorship W2116713827A5052690775 @default.
• W2116713827 hasAuthorship W2116713827A5069977124 @default.
• W2116713827 hasAuthorship W2116713827A5070257158 @default.
• W2116713827 hasBestOaLocation W21167138272 @default.
• W2116713827 hasConcept C126322002 @default.
• W2116713827 hasConcept C151032500 @default.
• W2116713827 hasConcept C16005928 @default.
• W2116713827 hasConcept C197934379 @default.
• W2116713827 hasConcept C2426938 @default.
• W2116713827 hasConcept C2776285725 @default.
• W2116713827 hasConcept C2777288759 @default.
• W2116713827 hasConcept C2777673923 @default.
• W2116713827 hasConcept C2781413609 @default.
• W2116713827 hasConcept C71924100 @default.
• W2116713827 hasConcept C98274493 @default.
• W2116713827 hasConceptScore W2116713827C126322002 @default.
• W2116713827 hasConceptScore W2116713827C151032500 @default.
• W2116713827 hasConceptScore W2116713827C16005928 @default.
• W2116713827 hasConceptScore W2116713827C197934379 @default.
• W2116713827 hasConceptScore W2116713827C2426938 @default.
• W2116713827 hasConceptScore W2116713827C2776285725 @default.
• W2116713827 hasConceptScore W2116713827C2777288759 @default.
• W2116713827 hasConceptScore W2116713827C2777673923 @default.
• W2116713827 hasConceptScore W2116713827C2781413609 @default.
• W2116713827 hasConceptScore W2116713827C71924100 @default.
• W2116713827 hasConceptScore W2116713827C98274493 @default.
• W2116713827 hasIssue "12" @default.
• W2116713827 hasLocation W21167138271 @default.
• W2116713827 hasLocation W21167138272 @default.
• W2116713827 hasLocation W21167138273 @default.
• W2116713827 hasOpenAccess W2116713827 @default.
• W2116713827 hasPrimaryLocation W21167138271 @default.
• W2116713827 hasRelatedWork W1953690218 @default.

• next